Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension

Autor: S. Bringhen, A. Milan, M. D'Agostino, C. Ferri, R. Wäsch, F. Gay, A. Larocca, M. Offidani, S. Zweegman, E. Terpos, H. Goldschmidt, M. Cavo, H. Ludwig, C. Driessen, H. W. Auner, J. Caers, M. Gramatzki, M. A. Dimopoulos, M. Boccadoro, H. Einsele, P. Sonneveld, M. Engelhardt
Přispěvatelé: Hematology, CCA - Cancer Treatment and quality of life, Anatomy and neurosciences, Bringhen, S, Milan, A, D'Agostino, M, Ferri, C, Wäsch, R, Gay, F, Larocca, A, Offidani, M, Zweegman, S, Terpos, E, Goldschmidt, H, Cavo, M, Ludwig, H, Driessen, C, Auner, H W, Caers, J, Gramatzki, M, Dimopoulos, M A, Boccadoro, M, Einsele, H, Sonneveld, P, Engelhardt, M
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
adverse event
030204 cardiovascular system & hematology
RECOMMENDATIONS
chemistry.chemical_compound
0302 clinical medicine
Prospective cohort study
AMERICAN SOCIETY
Multiple myeloma
LENALIDOMIDE
Hematology
carfilzomib
ASSOCIATION
DEXAMETHASONE
multiple myeloma
Cardiovascular Diseases
ECHOCARDIOGRAPHY
Life Sciences & Biomedicine
Oligopeptides
medicine.drug
CANCER-THERAPY
medicine.medical_specialty
cardiovascular toxicity
adverse events
blood pressure monitoring
clinical assessment
03 medical and health sciences
Medicine
General & Internal
General & Internal Medicine
Internal medicine
Internal Medicine
medicine
Humans
Adverse effect
Monitoring
Physiologic
Lenalidomide
Science & Technology
CARDIOMYOPATHY
business.industry
Decision Trees
1103 Clinical Sciences
medicine.disease
Carfilzomib
DYSFUNCTION
030104 developmental biology
Blood pressure
Cardiovascular System & Hematology
chemistry
Heart failure
business
CARDIOTOXICITY ROLE
Zdroj: Bringhen, S, Milan, A, D'Agostino, M, Ferri, C, Wäsch, R, Gay, F, Larocca, A, Offidani, M, Zweegman, S, Terpos, E, Goldschmidt, H, Cavo, M, Ludwig, H, Driessen, C, Auner, H W, Caers, J, Gramatzki, M, Dimopoulos, M A, Boccadoro, M, Einsele, H, Sonneveld, P & Engelhardt, M 2019, ' Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension ', Journal of Internal Medicine, vol. 286, no. 1, pp. 63-74 . https://doi.org/10.1111/joim.12882
Journal of Internal Medicine, 286(1), 63-74. Wiley-Blackwell
Journal of Internal Medicine, 286(1), 63-74. Wiley-Blackwell Publishing Ltd
ISSN: 0954-6820
DOI: 10.1111/joim.12882
Popis: The novel proteasome inhibitor carfilzomib alone or in combination with other agents is already one of the standard therapies in relapsed and/or refractory multiple myeloma (MM) patients and produces impressive response rates in newly diagnosed MM as well. However, carfilzomib-related cardiovascular adverse events (CVAEs) - including hypertension (all grades: 12.2%; grade ≥3: 4.3%), heart failure (all grades: 4.1%; grade ≥3: 2.5%) and ischemic heart disease (all grades: 1.8%; grade ≥3: 0.8%) - may lead to treatment suspensions. At present, there are neither prospective studies nor expert consensus on the prevention, monitoring and treatment of CVAEs in myeloma patients treated with carfilzomib. An expert panel of the European Myeloma Network in collaboration with the Italian Society of Arterial Hypertension and with the endorsement of the European Hematology Association aimed to provide recommendations to support health professionals in selecting the best management strategies for patients, considering the impact on outcome, the risk-benefit ratio of diagnostic and therapeutic tools and thereby to achieve myeloma response with novel combination approaches, while preventing CVAEs. Patients scheduled to receive carfilzomib need a careful cardiovascular evaluation before treatment and an accurate follow-up during treatment. A detailed clinical assessment before starting carfilzomib treatment is essential to identify patients at risk for CVAEs, and accurate monitoring of blood pressure and of early signs and symptoms suggestive of cardiac dysfunction remains pivotal to safely administer carfilzomib without treatment interruptions or dose reductions. This article is protected by copyright. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: